Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab

Overview

About this study

The purpose of this study is to evaluate T cell and antibody immunity in patients with HER2+ breast cancer who will receive trastuzumab with standard chemotherapy in order to address whether the immunity is associated with the patient’s response to treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Age >18 years.
Histological confirmation of clinically HER2+ breast cancer
Scheduled to start anti-HER2 therapy, in combination with chemotherapy, for breast cancer in the (neo)adjuvant or metastatic setting (including in combination with pertuzumab or other HER2 dimerization inhibitors). NOTE: Patients can have received prior anti-HER2 therapy if ≥3 months since last treatment.
Written informed consent obtained.
Willingness to provide blood samples for correlative research purposes

Exclusion Criteria:

Received prior anti-HER2+ therapy within less than 3 months
Are currently being treated with immune suppressive drugs for an autoimmune disease
Received prior immune suppressive therapy within the last 3 months

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla. Mayo Clinic principal investigator Keith Knutson, Ph.D.	Closed for enrollment	Contact information: Cancer Center Clinical Trials Referral Office 855-776-0015
Rochester, Minn. Mayo Clinic principal investigator Keith Knutson, Ph.D.	Closed for enrollment	Contact information: Cancer Center Clinical Trials Referral Office 855-776-0015
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Keith Knutson, Ph.D.	Closed for enrollment	Contact information: Cancer Center Clinical Trials Referral Office 855-776-0015

Mayo Clinic Location

Status

Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Keith Knutson, Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Keith Knutson, Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Keith Knutson, Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Clinical Trials